Sponsored content

Ranjan Narula and Suvarna Pandey of RNA Technology and IP Attorneys analyse the fiery ruling which declared ‘an order which contains reasons that no one can understand is worse than an unreasoned order’

At an exciting time in South Korea’s IP evolution, Min Son of Hanol IP & Law reports on the jurisdiction’s new user-friendly trademark measures.

Güldeniz Doğan Alkan and Cansu Evren of Gün + Partners say that a recent ruling raises the question of how many trademarks should be imitated for an act of bad faith to be recognised

There are several benefits to companies opting for a hybrid approach to IP rights management using a service provider, say experts from Zacco in their second article of a four-part series exploring some of the issues that are frequently raised by companies

Takanori Abe of Abe & Partners presents a personal account of his experience regarding presentations in court in Japan, the US, Germany, and the UK, and suggests cultural factors may explain the different approaches

Jorge Juárez of Olivares explains the requirements for applicants aiming to protect industrial designs in designating Mexico and highlights the importance of compliance with the unity of design requirement

Vera Albino, Legal Manager at Inventa, analyses some of the European copyright decisions in 2022 which dealt with human rights law

V Mohini and Sonal Goel of Remfry & Sagar say that the Indian courts are sending an increasingly clear message regarding the awarding of damages for the victims of IP crimes

In the first article of a four-part series, IP experts from across Zacco explore some of the issues that are frequently raised by companies, beginning with addressing some of the complexities of entering the European market from abroad and explaining what approaches could be taken

With this expansion of the partner team, V.O. is even better able to serve the growing customer base within the Chemistry and Life Sciences sections

The healthcare sector in Brazil is one of the most important in the world in view of the size of the population (+220 million people) and the availability of a universal public healthcare system. The action of antibodies as therapeutic agents may involve processes of neutralization, opsonization and activation of immune complement system, transforming them into a progressively desirable tool in medicine. In view of this, the interaction between IP and these innovative therapies deserves special attention.

A shift is required in the finance and banking sectors’ approach to the use of intangible capital assets as collateral, says Marco Stief of Maiwald